Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Broadly neutralizing antibodies (bnAbs) can delay HIV rebound and even lead to long-term remission.
Two broadly neutralizing antibodies delayed HIV rebound in people who started antiretroviral therapy early.
One person treated with a broadly neutralizing antibody plus romidepsin remained in remission for 3.7 years.
A combination of two antibodies, dubbed 3BNC117 and 10-1074, maintained viral suppression for a year in two people.
The experimental vaccine regimen aims to train B cells to produce broadly neutralizing antibodies against HIV.
The experimental vaccines use the same technology as the highly effective Moderna COVID-19 shot.
With $600,000 in amfAR HIV grants, research teams explore CAR-T cells, bFAbs and CRISPR/Cas9 gene editing to eradicate the reservoir.
Two experimental vaccine approaches, using mRNA protein delivery and germline targeting, are in the early stages of development.
HIV treatment usually requires daily pills, but longer-acting regimens are gaining ground.
That’s the hope of research funded by a new Campbell Foundation grant.
Products based on broadly neutralizing antibodies could be used in HIV treatment and prevention.
The new coronavirus crisis has upended the clinical trials process around the world.
Researchers used a harmless virus to deliver a gene for a broadly neutralizing HIV antibody to cells, which produced the antibody over time.
Temporarily off antiretrovirals, participants received antibody injections, which boosted CD4 and CD8 cell responses to HIV.
For the first time, researchers are assessing a pairing of a long-acting antiretroviral and a long-acting antibody.
An $80,000 grant from The Campbell Foundation will help scientist Natalia Freund continue her HIV vaccine studies.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.